1207326-19-9

Basic information

• Product Name: N-[(1S)-1-[[[(1S)-1-[(3aR,4R,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-phenyl]-1-(S)-(-)-1,2,3,4-tetrahydro-naphthoiccarboxamide
• Synonyms: N-[(1S)-1-[[[(1S)-1-[(3aR,4R,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-phenyl]-1-(S)-(-)-1,2,3,4-tetrahydro-naphthoiccarboxamide
• CAS NO: 1207326-19-9
• Molecular Weight: 570.58
• Mol File: 1207326-19-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-[(1S)-1-[[[(1S)-1-[(3aR,4R,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-phenyl]-1-(S)-(-)-1,2,3,4-tetrahydro-naphthoiccarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(1S)-1-[[[(1S)-1-[(3aR,4R,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-phenyl]-1-(S)-(-)-1,2,3,4-tetrahydro-naphthoiccarboxamide(1207326-19-9)
• EPA Substance Registry System: N-[(1S)-1-[[[(1S)-1-[(3aR,4R,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-phenyl]-1-(S)-(-)-1,2,3,4-tetrahydro-naphthoiccarboxamide(1207326-19-9)

Safety Data

• Hazardous Substances Data: 1207326-19-9(Hazardous Substances Data)

Upstream product

• 1173166-93-2 C₂₀H₂₁NO₃ 
• 1173167-11-7 (S)-(1-amino-3-methylbutyl)boronic acid (1R,2R,3S,5R)-(-)-2,3-pinanediol ester hydrochloride salt 

Downstream Products

• 1173166-90-9 [(1S)-1-[[(2S)-3-phenyl-2-[((S)-(-)-1,2,3,4-tetrahydro-naphthoic-1-carbonyl)amino]-1-oxopropyl]amino]-3-methylbutyl]boronic acid 

Relevant articles and documents

Design, synthesis, biological evaluation, and Structure-Activity Relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, Part I: Comprehensive understanding of the SAR of α-amino acid boronates

New series of dipeptidyl boronate inhibitors of 20S proteasome were designed and synthesized. The comprehensive understanding of the SAR was obtained by utilizing the variation of four substituents. From the screened compounds in enzyme, novel inhibitors 49 and 50 were identified to be highly potent druglike candidates with IC50 values of 1.2 and 1.6 nM, respectively, which showed better activities than the drug bortezomib on the market. Two hematologic human tumor cell lines, HL-60 and U266, were significantly sensitive to both candidates and showed nearly the same potency as the standard bortezomib with IC50 values less than 10 nM. But as for most of the eight human solid tumor cell lines, both candidates were more potent than the standard with the IC50 value range of 9.8-70 nM. The activity evaluation of the stereoisomers showed that changing R-isomers to S-isomers greatly reduced the potency and even induced inactivity.